Pradžia › Ūmi bifeninė leukemija › Pennsylvania
Ūmi bifeninė leukemija klinikiniai tyrimai Pennsylvania
6 tyrimai dėl Ūmi bifeninė leukemija ieško dalyvių vietose Pennsylvania.
Miestai Pennsylvania
Oficialus tyrimo tekstas (anglų kalba)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- ir dar 2
Renkami dalyviai2 fazė
365 Days · Visoms lytims · Atnaujinta 2026-09-25 · NCT06317662A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Pennsylvania, Philadelphia
Renkami dalyviai1/2 fazė
30 Days · Visoms lytims · Atnaujinta 2026-09-16 · NCT04065399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- ir dar 3
Renkami dalyviai3 fazė
365 Days – 25 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- ir dar 3
Renkami dalyviai1/2 fazė
Iki 22 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT04726241Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviai1 fazė
Amžius nuo 1 iki 30 · Visoms lytims · Atnaujinta 2026-08-03 · NCT06177067Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviai1 fazė
Amžius nuo 1 iki 21 · Visoms lytims · Atnaujinta 2024-12-06 · NCT05476770Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.